For Employers Government Agencies

The novel coronavirus disease (COVID-19) is a new virus of global health significance caused by infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). On March 11, 2020, the World Health Organization (WHO) declared COVID-19 a global pandemic.

Thank you for reading this post, don't forget to subscribe!

At AGPC, our priority remains in the health and safety of the communities we serve, and we are doing our part to deliver answers during these uncertain times. For employers and government authorities, testing for antibodies is the next logical step to help guide decisions about moving forward. AGPC  is proud to collaborate with host organizations to provide laboratory and testing services that help identify:

• If an individual has detectable COVID-19 antibodies
• How many people were infected in a geographic area
• How the number of infected people is changing over time
• Types of populations that may be at a higher risk of infection
• How many people were infected with mild or no symptoms

Antibodies are proteins produced by the body’s immune system to try to fight infection. AGPC offers a test that utilizes a blood sample to measure SARS-CoV-2 specific antibody levels, which correlate with a patient’s immune response after COVID-19 infection. Based on early evidence, antibodies are is expected to be elevated in the majority of patients by 14 days after the onset of symptoms. The timeline for antibody elevation in asymptomatic patients is still being studied.

AGPC offers an immunoassay for antibody testing with high sensitivity and specificity. Each COVID-19 antibody test is performed utilizing the Roche Elecsys Anti-Sars CoV-2 assay or the DiaSorin Liaison Sars CoV-2 S1/S2 assay. These high-volume instruments have been verified for accuracy. They have been approved by appropriate state Departments of Health, and are being used under FDA Emergency Use Authorizations (EUA).

Test results play a critical role in the fight against COVID-19 by identifying who has detectable antibodies. Together with other clinical information and guidance from health authorities, these results can assist with decisions on ensuring the safety of employees and customers.

Many COVID-19 patients have mild or no symptoms, and may not have been diagnosed when infected. Antibody testing can provide employers key information about who has been infected, and who may potentially be immune from re-infection when making decisions on returning to work and implementing workplace safety procedures.